Stepping forward in antibody-drug conjugate development

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) combine targeted antibody delivery with potent cytotoxic payloads.
• ADCs leverage antibody specificity to direct toxic agents to tumor cells, minimizing systemic toxicity.
• The mechanism involves antibody binding, tumor cell internalization, payload release in lysosomes, and subsequent cancer cell death via apoptosis or bystander effects.

Purpose of the Study:

• To review recent clinical research on antibody-drug conjugates (ADCs).
• To analyze how the in vivo processing of ADCs influences their therapeutic design.
• To provide comprehensive information to aid future ADC development.

Main Methods:

• Literature review of recent clinical studies on ADCs.
• Analysis of ADC processing pathways within the body (in vivo).
• Focus on the relationship between ADC processing and drug design strategies.

Main Results:

• Significant increase in ADC approvals from 2011-2020, indicating growing clinical development.
• Understanding in vivo processing is crucial for optimizing ADC efficacy and safety.
• Recent research highlights advancements in ADC design informed by their biological fate.

Conclusions:

• ADCs represent a rapidly advancing class of cancer therapeutics.
• Further research into ADC in vivo processing will drive the development of more effective and targeted cancer treatments.
• This review synthesizes current knowledge to guide future ADC innovation.